Coeptis Files 10-K/A, Clarifies Warrant Terms on Nasdaq

Ticker: COEPW · Form: 10-K/A · Filed: Jun 3, 2025 · CIK: 1759186

Sentiment: neutral

Topics: 10-K/A, SEC Filing, Biotechnology, Compliance, Warrants, Nasdaq, Amendment

Related Tickers: COEP, COEPW

TL;DR

**COEPW's 10-K/A is a routine compliance update, confirming warrant terms and filing status, but offers no new financial catalysts.**

AI Summary

Coeptis Therapeutics Holdings, Inc. (COEPW) filed a 10-K/A Amendment No. 1 for the fiscal year ended December 31, 2024, primarily to amend its annual report. The filing confirms the company's status as a non-accelerated filer and indicates it has filed all required reports under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months. The amendment also clarifies the trading symbols for its Common Stock (COEP) and Warrants (COEPW) on the Nasdaq Capital Market. The warrants are exercisable for one-half of one share of Common Stock for $230.00 per whole share. While the amendment itself does not introduce new financial figures for revenue or net income, it ensures compliance and accuracy of previously reported information. The company's business address remains 105 Bradford Road, Suite 420, Wexford, Pennsylvania 15090. This filing is a procedural update, not a substantive change to financial performance or strategic outlook.

Why It Matters

This 10-K/A filing is a procedural amendment, primarily ensuring Coeptis Therapeutics Holdings, Inc. (COEPW) remains compliant with SEC reporting requirements. For investors, it confirms the accuracy of previously filed information, particularly regarding the terms of its warrants, which are exercisable at $230.00 per whole share for one-half of one common share. While not a game-changer, consistent and accurate filings build investor confidence and maintain market transparency, especially for a smaller reporting company in the competitive biotech sector. Employees and customers are unlikely to be directly impacted by this administrative update.

Risk Assessment

Risk Level: low — The risk level is low because this 10-K/A is an amendment to a previously filed annual report, primarily for compliance and clarification purposes. It does not introduce new financial risks, operational changes, or adverse events. The filing confirms Coeptis has met its reporting obligations, indicating good corporate governance regarding SEC filings.

Analyst Insight

Investors should view this 10-K/A as a routine administrative update, not a signal for immediate action. It confirms the company's compliance and the previously stated terms of its COEPW warrants. Focus on the underlying business fundamentals and future pipeline developments rather than this procedural filing.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of Coeptis Therapeutics Holdings, Inc.'s 10-K/A filing?

The 10-K/A filing by Coeptis Therapeutics Holdings, Inc. (COEPW) is an Amendment No. 1 to its annual report for the fiscal year ended December 31, 2024. Its primary purpose is to amend and clarify information, ensuring compliance with SEC reporting requirements, such as confirming its non-accelerated filer status and the terms of its warrants.

What are the exercise terms for Coeptis Therapeutics' (COEPW) warrants?

Coeptis Therapeutics Holdings, Inc.'s (COEPW) warrants are each exercisable for one-half of one share of Common Stock for $230.00 per whole warrant. This detail was confirmed in the 10-K/A filing for the fiscal year ended December 31, 2024.

Is Coeptis Therapeutics Holdings, Inc. (COEPW) compliant with SEC reporting requirements?

Yes, the 10-K/A filing indicates that Coeptis Therapeutics Holdings, Inc. (COEPW) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and has been subject to such filing requirements for the past 90 days.

What is the fiscal year end covered by Coeptis Therapeutics' (COEPW) 10-K/A?

The 10-K/A filed by Coeptis Therapeutics Holdings, Inc. (COEPW) is for the fiscal year ended December 31, 2024. This amendment updates the annual report for that specific period.

Where is Coeptis Therapeutics Holdings, Inc.'s (COEPW) principal executive office located?

Coeptis Therapeutics Holdings, Inc.'s (COEPW) principal executive office is located at 105 Bradford Road, Suite 420, Wexford, Pennsylvania 15090. This information is consistent across its filings, including the recent 10-K/A.

What is the trading symbol for Coeptis Therapeutics Holdings, Inc.'s common stock?

The trading symbol for Coeptis Therapeutics Holdings, Inc.'s common stock is COEP, and it is registered on the Nasdaq Capital Market. This was confirmed in the 10-K/A filing.

Does the 10-K/A filing introduce new financial results for Coeptis Therapeutics (COEPW)?

No, the 10-K/A filing for Coeptis Therapeutics Holdings, Inc. (COEPW) is an amendment for clarification and compliance, not a release of new financial results. It does not contain updated revenue, net income, or other financial performance figures beyond what was in the original 10-K.

What is Coeptis Therapeutics Holdings, Inc.'s (COEPW) status regarding being a well-known seasoned issuer?

Coeptis Therapeutics Holdings, Inc. (COEPW) is not a well-known seasoned issuer, as indicated by the check mark in its 10-K/A filing. This status is defined in Rule 405 of the Securities Act.

What type of filer is Coeptis Therapeutics Holdings, Inc. (COEPW)?

Coeptis Therapeutics Holdings, Inc. (COEPW) is a non-accelerated filer. This status is explicitly stated in its 10-K/A filing, distinguishing it from large accelerated or accelerated filers.

How does this 10-K/A impact investors in Coeptis Therapeutics (COEPW)?

For investors, this 10-K/A filing primarily serves as a confirmation of Coeptis Therapeutics Holdings, Inc.'s (COEPW) ongoing compliance with SEC regulations and clarifies existing information, such as warrant terms. It does not present new financial opportunities or risks, so investors should not expect immediate market impact from this administrative update.

Industry Context

The biotechnology and pharmaceutical industry is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Companies in this sector often focus on developing novel therapeutics, and success is heavily dependent on clinical trial outcomes and market adoption. The competitive landscape includes both large, established pharmaceutical companies and numerous smaller, innovative biotech firms.

Regulatory Implications

As a biotechnology company, Coeptis Therapeutics Holdings, Inc. is subject to stringent regulatory oversight from bodies like the FDA. Compliance with Good Manufacturing Practices (GMP), clinical trial regulations, and reporting requirements is critical. Any failure to adhere to these regulations can lead to significant delays, fines, or product rejection, impacting the company's ability to bring therapies to market.

What Investors Should Do

  1. Review the full amended 10-K filing for any specific details or clarifications that may have been added, even if the amendment is procedural.
  2. Monitor future filings for substantive updates on clinical development, partnerships, or financial performance.
  3. Understand the terms of the warrants (COEPW), particularly the high exercise price of $230.00 for half a share.

Glossary

10-K/A
An amended annual report filed with the SEC. It is used to correct or update information previously filed in a Form 10-K. (This filing is an amendment to Coeptis Therapeutics Holdings, Inc.'s annual report, indicating a procedural update to previously submitted information.)
Non-accelerated filer
A filer that does not meet the criteria for accelerated or large accelerated filer status, typically based on public float and filing history. They have fewer reporting obligations. (Coeptis Therapeutics Holdings, Inc. is identified as a non-accelerated filer, which is a status relevant to its reporting requirements.)
Section 13 or 15(d) of the Securities Exchange Act of 1934
Sections of the Securities Exchange Act of 1934 that mandate periodic reporting requirements for companies whose securities are registered with the SEC. (The filing confirms that Coeptis Therapeutics Holdings, Inc. has met its reporting obligations under these sections for the preceding 12 months.)
Common Stock Par Value
A nominal value assigned to a share of stock by the company's charter, often a very small amount like $0.0001. (The par value for Coeptis Therapeutics Holdings, Inc.'s common stock (COEP) is stated as $0.0001 per share.)
Warrants
Securities that give the holder the right, but not the obligation, to purchase a company's stock at a specified price (exercise price) before a certain expiration date. (The filing details Coeptis Therapeutics Holdings, Inc.'s warrants (COEPW), including their exercise price and the number of shares they are exercisable for.)

Year-Over-Year Comparison

This filing is an amendment (10-K/A) to the annual report for the fiscal year ended December 31, 2024. As it is an amendment to correct or clarify previously filed information, it does not represent a new reporting period. Therefore, a direct comparison of key metrics like revenue growth, margin changes, or new risks to a previous year's filing is not applicable in the context of this specific amendment. The primary purpose is to ensure the accuracy and completeness of the original 10-K filing.

Filing Details

This Form 10-K/A (Form 10-K/A) was filed with the SEC on June 3, 2025 regarding Coeptis Therapeutics Holdings, Inc. (COEPW).

View full filing on EDGAR

View Full Filing

View this 10-K/A filing on SEC EDGAR

View on Read The Filing